Profund Advisors’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$663K Sell
3,499
-101
-3% -$19K 0.02% 458
2026
Q1
$710K Sell
3,600
-23,436
-87% -$4.52M 0.03% 445
2025
Q4
$4.97M Buy
27,036
+2,342
+9% +$411K 0.15% 102
2025
Q3
$3.79M Sell
24,694
-1,782
-7% -$270K 0.12% 117
2025
Q2
$3.7M Buy
26,476
+3,407
+15% +$477K 0.13% 114
2025
Q1
$3.39M Sell
23,069
-1,482
-6% -$214K 0.15% 109
2024
Q4
$3.22M Buy
24,551
+1,943
+9% +$272K 0.12% 125
2024
Q3
$3.52M Sell
22,608
-1,994
-8% -$322K 0.13% 114
2024
Q2
$3.84M Sell
24,602
-187
-0.8% -$28.1K 0.14% 106
2024
Q1
$3.36M Sell
24,789
-1,729
-7% -$229K 0.13% 119
2023
Q4
$3.57M Buy
26,518
+3,555
+15% +$462K 0.15% 114
2023
Q3
$3.11M Buy
22,963
+5,040
+28% +$688K 0.17% 102
2023
Q2
$2.57M Sell
17,923
-992
-5% -$146K 0.14% 117
2023
Q1
$2.63M Sell
18,915
-311
-2% -$41.8K 0.16% 107
2022
Q4
$2.61M Buy
19,226
+841
+5% +$105K 0.17% 111
2022
Q3
$2.02M Sell
18,385
-1,168
-6% -$148K 0.15% 130
2022
Q2
$2.58M Sell
19,553
-3,736
-16% -$490K 0.16% 117
2022
Q1
$3.09M Buy
23,289
+15,466
+198% +$1.85M 0.13% 134
2021
Q4
$911K Buy
7,823
+18
+0.2% +$2.12K 0.03% 358
2021
Q3
$938K Buy
7,805
+325
+4% +$37.8K 0.03% 380
2021
Q2
$896K Buy
7,480
+199
+3% +$21.8K 0.03% 390
2021
Q1
$724K Buy
7,281
+257
+4% +$25.8K 0.03% 415
2020
Q4
$702K Buy
7,024
+677
+11% +$71.7K 0.03% 414
2020
Q3
$696K Sell
6,347
-1,800
-22% -$200K 0.04% 364
2020
Q2
$862K Buy
8,147
+1,478
+22% +$153K 0.05% 290
2020
Q1
$596K Sell
6,669
-2,043
-23% -$192K 0.04% 313
2019
Q4
$869K Sell
8,712
-2,222
-20% -$209K 0.04% 393
2019
Q3
$975K Sell
10,934
-1,460
-12% -$127K 0.05% 341
2019
Q2
$1.02M Buy
12,394
+172
+1% +$13.5K 0.05% 360
2019
Q1
$988K Buy
12,222
+2,003
+20% +$158K 0.05% 340
2018
Q4
$776K Sell
10,219
-4,081
-29% -$319K 0.05% 340
2018
Q3
$1.13M Sell
14,300
-250
-2% -$18.9K 0.04% 356
2018
Q2
$1.02M Sell
14,550
-800
-5% -$57.6K 0.04% 367
2018
Q1
$1.07M Sell
15,350
-12,450
-45% -$862K 0.04% 382
2017
Q4
$1.93M Sell
27,800
-3,244
-10% -$219K 0.07% 244
2017
Q3
$2.1M Buy
31,044
+8,372
+37% +$529K 0.09% 209
2017
Q2
$1.55M Sell
22,672
-6,136
-21% -$401K 0.07% 254
2017
Q1
$1.79M Buy
28,808
+9,724
+51% +$566K 0.08% 222
2016
Q4
$1.04M Buy
19,084
+730
+4% +$41.5K 0.05% 409
2016
Q3
$1.21M Buy
18,354
+1,518
+9% +$99.2K 0.06% 315
2016
Q2
$1.02M Sell
16,836
-4,232
-20% -$246K 0.05% 382
2016
Q1
$1.19M Buy
21,068
+1,150
+6% +$69.1K 0.06% 289
2015
Q4
$1.35M Buy
19,918
+2,852
+17% +$187K 0.06% 254
2015
Q3
$1.09M Sell
17,066
-8,694
-34% -$572K 0.06% 264
2015
Q2
$1.64M Buy
25,760
+598
+2% +$40.9K 0.07% 236
2015
Q1
$1.72M Buy
25,162
+4,830
+24% +$336K 0.07% 259
2014
Q4
$1.43M Sell
20,332
-4,454
-18% -$319K 0.06% 298
2014
Q3
$1.77M Sell
24,786
-14,094
-36% -$1.03M 0.08% 214
2014
Q2
$2.89M Buy
38,880
+6,804
+21% +$492K 0.13% 133
2014
Q1
$2.08M Sell
32,076
-1,728
-5% -$112K 0.09% 170
2013
Q4
$2.01M Buy
33,804
+4,241
+14% +$230K 0.09% 178
2013
Q3
$1.53M Buy
29,563
+13,254
+81% +$666K 0.08% 230
2013
Q2
$771K Buy
+16,309
New +$830K 0.05% 377

Other funds holding AZN

Profund Advisors's AZN Position: Q2 2026 in Review

Profund Advisors reduced its AstraZeneca (AZN) stake by 2.8% in Q2 2026, selling an estimated $19K and leaving 3,499 shares worth $663K. The position accounts for 0.02% of the portfolio, ranked #458.

Profund Advisors first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.97M in Q4 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Profund Advisors held 3,499 shares of AstraZeneca worth $663K as of Q2 2026.
  • Profund Advisors sold 101 AstraZeneca shares in Q2 2026, an estimated $19K.
  • AstraZeneca made up 0.02% of Profund Advisors's portfolio in Q2 2026, its #458 holding.
  • Profund Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
  • Profund Advisors's AstraZeneca position peaked at $4.97M in Q4 2025.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.